Biologicals have revolutionised modern medicine by offering vital therapeutic options to treat or prevent complex, disabling, and life-threatening diseases.

Prof Zelenetz opened the symposium on the evolving front-line treatment options for follicular lymphoma (FL) and discussed the potential of novel agents…

The Alexion satellite symposium was introduced by Prof Pier Mannuccio Mannucci who provided an introduction to the history of thrombotic…

CD30-positive (CD30+) lymphomas are a heterogeneous group of hematological malignancies that share the same antigen. Over recent decades, advances…

While the standard of care for chronic lymphocytic leukaemia (CLL) leads to high overall response rates and a long progression-free survival, it can be…

Chronic lymphocytic leukaemia (CLL) is a clinically heterogeneous disease characterised by the accumulation/expansion of a clonal population of…

In the last decades, advances in the therapeutic management of multiple myeloma (MM) with new drug armamentarium and strategies have significantly…

Autologous stem cell transplantation (ASCT) is considered the standard of care for multiple myeloma patients aged <65 years with no relevant…

Patients diagnosed with myeloproliferative neoplasms (MPNs) often develop thrombotic events as an onset of symptoms or in evolution. The pathogenesis of…

Calreticulin (CALR), a Ca2+ binding protein mostly localised in the endoplasmic reticulum, regulates Ca2+ homeostasis, chaperones, and other proteins to…